You can scroll left and right to view the full content.

MyoLac II (vFT005): Injectable treatment for enhancing pig productivity

Therapy mechanism of MyoLac II

View Image

[Target animal efficacy test (XP Bio test): 1-week-old pigs, two injections (6-month study)]

• Safety (Low, Medium, High dosage): administrated two intramuscular injections with concentrations of 1.0x10⁸, 1.0x10⁹, 1.0x10¹⁰ cells/head, where the control and treated groups showed no significant differences in mortality or generic symptoms
• Validation of efficacy: dosages of 1.0x10⁸ and 1.0x10⁹ cells/head resulted in average 13.5% and 10.8% weight gain, respectively.
• Formation of anti-myostatin antibody was confirmed in treated groups (antibody formation showed meaningful correlation with weight gain)
• Identified optimal dosage

Background for the development of livestock enhancement pharmaceutical MyoLac II

View Image

Expected benefits of developing MyoLac II seen through productivity uplift in pigs

• 
  • Enhanced productivity leads to a 30% increase in farm profitability (for an average domestic farm with 200 sows, net profit increases from KRW 320 million to KRW 440 million)
  • Replaces pork imports [expected 26% reduction in annual pork import from 374,000 tons (additional domestic production of 106,000 tons with enhanced productivity)]
  • Since the amino acid sequence for mature (active) myostatin are 98-100% identical in vertebrates, the technology could be extended across various livestock species to improve productivity.
  • Normalizes and improves growth of underweight and weakened piglets (unmet medical needs remain to date), shortening time to market and enhancing productivity
• 
  • Addresses global meat supply imbalance by improving the productivity of industrial animals
  • Prevent the emergence of multiple antibiotic-resistant bacteria by replacing antibiotic feed additives that may leak out to the environment (such bacteria are expected to cause 2 million deaths globally by 2050)
  • Provide safe meat to consumers by replacing growth hormone treatments, which are currently banned from use due to human safety concerns.

Market analysis and technology characeristics

View Image

View Image

Changes in governmental policies

1. Regulations restricting the use of antibiotics and growth hormones for increased meat yield
   • Regulations on the use of antibiotics
     : Banned the use of antibiotic additives in compound feed from July 2011
     : 2026, Global antibiotics market in livestock: 2021, USD 4.7 billion (CAGR: 3.6%), 2026 antibiotics market: USD 4.16 billion, 73.4% of total USD 5.6 billion (KRW 5.6 trillion) was used in livestock sector
   • Regulations on growth hormone treatments
     : Designated as a risk element in terms of safety and efficacy
     (Animal and Plant Quarantine Agency, Scope and tolerance thresholds of harmful substances in feed [related to Article 11, Paragraph 1])
     : 2023, Global beta agonist feed additives market: USD 89 billion (KRW 120 trillion)
2. Introduction of eco-friendly livestock certification program (November 2020)
   • There is urgent need for new pharmaceuticals certified as eco-friendly that can replace antibiotics and growth hormone treatments

Development benefits

View Image